All In Biotech

Drug Trial Radar · NCT06244082

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

A Phase 2 Open-label Study to Evaluate the Pharmacodynamics and Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants With Mutations Amenable to Exon 44 Skipping

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

39

Actual

Start

Jan 22, 2024

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Avidity Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Feb 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 7 years, up to 27 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.

Conditions

  • DMD
  • Duchenne Muscular Dystrophy
  • Duchenne
  • Exon 44

Interventions

  • AOC 1044Drug

    AOC 1044 will be administered via intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: Through study completion (approximately 2 years)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of California, San Diego, Rady's Children's Hospital

    La Jolla, California

  • UC Davis Medical Center

    Sacramento, California

  • Lucille Packard Children's Hospital at Stanford

    San Carlos, California

  • Rare Disease Research - Atlanta

    Atlanta, Georgia

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota

  • Rare Disease Research

    Hillsborough, North Carolina

  • Abigail Wexner Research Institute at Nationwide Children's Hospital

    Columbus, Ohio

  • Neurology Rare Disease Center

    Denton, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.